Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2008

01-05-2008 | Poster presentation

De novo expression of αvβ6 integrin by myoepithelial cells in ductal carcinoma in situ may be an important marker of disease progression

Authors: M Allen, K Mulligan, S Clark, I Hart, JF Marshall, JL Jones

Published in: Breast Cancer Research | Special Issue 2/2008

Login to get access

Excerpt

Myoepithelial cells (MEC) are essential to the maintenance of normal breast function, and loss of normal MEC function is commonly associated with breast cancer. Most established invasive breast carcinomas develop through an in situ phase known as ductal carcinoma in situ (DCIS). We have identified up-regulation of β6 integrin on MEC in a subset of DCIS. Normal MEC exhibit potent tumour suppressor function, but it is not clear whether this is compromised in DCIS. The aim of the present study is to investigate the effect of β6 expression on myoepithelial tumour suppressor function. …
Metadata
Title
De novo expression of αvβ6 integrin by myoepithelial cells in ductal carcinoma in situ may be an important marker of disease progression
Authors
M Allen
K Mulligan
S Clark
I Hart
JF Marshall
JL Jones
Publication date
01-05-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1912

Other articles of this Special Issue 2/2008

Breast Cancer Research 2/2008 Go to the issue

Poster presentation

Prospective Study of Outcome in Sporadic versus Hereditary Breast Cancer: pros and cons of running a cohort study

Poster presentation

The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial

Poster presentation

Food choice and phytoestrogen consumption in women previously treated for postmenopausal breast cancer

Poster presentation

Breast cancer and environmental risk factors: an appraisal of the scientific evidence

Lecture presentation

Surviving breast cancer: can women expect to 'get back to normal'?

Poster presentation

Actions of IGF-I are differentially regulated by fatty acids in normal and breast cancer epithelial cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits